The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk agreed to pay up to $2 billion for the rights to ... hormones and is in early-stage clinical development for the ...

Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4 Becker’s contributions to the campaign, meanwhile, include Type 2 diabetes-friendly twists on recipes ...

Shares of Novo Nordisk dropped Monday after the company reported that its next-generation obesity drug produced weight loss results in diabetes patients that fell short of investors ...

(Bloomberg) -- Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot CagriSema. The medicine helped patients with diabetes ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...